At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 750 enrolled
Drug / intervention
PG324 Ophthalmic Solution 0.02%/0.005% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Double-masked, Randomized, Multi-center, Active Controlled, Parallel-group, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution 0.02% and Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure
In Brief
A Phase 3 clinical trial evaluating PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, and 1 other intervention for Open-angle Glaucoma and Ocular Hypertension. Completed, enrolled 750 participants across 1 site.
Detailed Summary
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedFeb 2016
Primary CompletionMar 2017
TodayJul 2026
First PostedFeb 5, 2016
Enrollment StartFeb 1, 2016
Primary CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.4 years ago
Interventions
PG324 Ophthalmic Solution 0.02%/0.005%drug
1 drop daily in the evening (PM) in both eyes (OU)
Netarsudil (AR-13324) ophthalmic solution 0.02%drug
1 drop daily in the evening (PM) in both eyes (OU)
Latanoprost ophthalmic solution 0.005%drug
1 drop daily in the evening (PM) in both eyes (OU)